Healthcare Industry News: Pulse Oximetry
News Release - November 18, 2008
Nihon Kohden Expands Integration of Masimo SET(R) Pulse Oximetry Technology WorldwideAgreement with Japan's leading medical equipment provider broadens availability of Masimo SET to the global clinical community
IRVINE, Calif., Nov. 18 (Healthcare Sales & Marketing Network) -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion Pulse Oximetry, and Nihon Kohden, one of the largest patient monitoring companies in the world, jointly announce an expanded technology licensing agreement that calls for the integration of Masimo SET into Nihon Kohden bedside and patient monitoring products worldwide.
"Growing clinical preference for Masimo SET continues to drive Pulse Oximetry technology selection for our customers," stated Kazuo Ogino, Chairman and CEO of Nihon Kohden. "We began integrating Masimo SET into Nihon Kohden products in the U.S. and Canada in 2006. The demand for Masimo technology worldwide continues to grow and we want to provide our customers with their preference of Pulse Oximetry technology. I believe the collaboration between Masimo and Nihon Kohden will create a great opportunity for our customers who look for an effective and reliable patient monitoring solution."
An important contributor in the advancement of modern medical treatment, Nihon Kohden is responsible for the invention of Pulse Oximetry. Today, with subsidiaries in the USA, Europe and Asia, and distributors in nearly every country in the world, Nihon Kohden is Japan's leading manufacturer, developer and distributor of medical electronic equipment, including: patient monitors, defibrillators, ECGs, EEGs, EP/EMGs, and hematology analyzers.
Masimo Founder and CEO, Joe E. Kiani, stated, "We look forward to continuing our partnership with Nihon Kohden to deliver advanced Pulse Oximetry solutions to customers in every part of the world. The expansion of our technology license broadens clinical access to 'gold standard' Masimo SET Pulse Oximetry and reinforces Nihon Kohden's continued commitment to customer satisfaction."
About Nihon Kohden Corporation
Nihon Kohden is Japan's leading manufacturer, developer and distributor of patient monitors, defibrillators, ECGs, EEGs, EP/EMGs, hematology analyzers and other medical electronic equipment, with subsidiaries in the United States, Europe, and Asia, and distributors in nearly every country in the world. Nihon Kohden is a publicly held company listed in the First Section of the Tokyo Stock Exchange. In addition to designing medical equipment for hospital and clinic use, Nihon Kohden actively contributes to the advance of medical technology. For more information, visit the Company's web site at http://www.nihonkohden.com.
Masimo (NASDAQ: MASI ) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion Pulse Oximetry, known as Masimo SET, which virtually eliminated false alarms and increased Pulse Oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET Pulse CO-Oximetry continuously and noninvasively measures total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumption that this worldwide Masimo SET technology license agreement with Nihon Kohden will serve to increase market acceptance and adoption of the technology, and risk related to our assumption that this technology licensing agreement will serve to substantially increase revenues, as well as other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2008, filed with the Securities and Exchange Commission ("SEC") on October 29, 2008, which may be obtained for free at the SEC's website at http://www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2008, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.